Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L5VS
|
||||
| Former ID |
DNC004457
|
||||
| Drug Name |
KF-17837
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Parkinson's disease [ICD9: 332; ICD10:G20] | Phase 1 | [546031] | ||
| Formula |
C22H28N4O4
|
||||
| Canonical SMILES |
CCCN1C2=C(C(=O)N(C1=O)CCC)N(C(=N2)C3=CC(=C(C=C3)OC)OC)C
|
||||
| InChI |
1S/C20H26N4O4/c1-6-10-23-18-16(19(25)24(11-7-2)20(23)26)22(3)17(21-18)13-8-9-14(27-4)15(12-13)28-5/h8-9,12H,6-7,10-11H2,1-5H3
|
||||
| InChIKey |
FSUNYKAEJIVAHY-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [525962] | |
| Adenosine A2a receptor | Target Info | Inhibitor | [533955] | ||
| Adenosine A2b receptor | Target Info | Inhibitor | [533955] | ||
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Morphine addictionhsa04015:Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| Vascular smooth muscle contraction | |||||
| Parkinson's disease | |||||
| Alcoholismhsa04015:Rap1 signaling pathway | |||||
| Alcoholism | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor networkcmyb_pathway:C-MYB transcription factor network | ||||
| References | |||||
| Ref 525962 | J Med Chem. 2001 Jan 18;44(2):170-9.2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor. | ||||
| Ref 533955 | J Med Chem. 1993 Nov 12;36(23):3731-3.Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.